ArticleAnnals of hematology2022

Polatuzumab vedotin combined with rituximab-bendamustine immediately before stem cell mobilization in relapsed diffuse large B-cell lymphoma.

Teruhito Takakuwa et al.PubMed ↗Publisher ↗

No numbers read from the abstract.